Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Fineline Cube May 6, 2026
Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Fineline Cube May 6, 2026
Company Deals

Henlius Biotech and Palleon Pharmaceuticals Modify Licensing Agreement for Bifunctional Antibody

Fineline Cube May 22, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Legal / IP

GSK Confronted with Whistleblower Allegations Over Zantac and NDMA Link

Fineline Cube May 22, 2024

GlaxoSmithKline (GSK; NYSE: GSK), the UK-based pharmaceutical giant, is facing legal action in the form...

Company Deals

Astellas Pharma Considers Joint Cell Therapy Platform with Yaskawa Electric

Fineline Cube May 22, 2024

Astellas Pharma Inc. (TYO: 4503), a leading Japanese pharmaceutical company, has announced that it is...

Company Deals

Sanofi Leads Pharma Industry with AI Collaboration with Formation Bio and OpenAI

Fineline Cube May 22, 2024

Sanofi (NASDAQ: SNY), the France-based multinational pharmaceutical company, has announced a cutting-edge collaboration with US...

Company Drug

Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment

Fineline Cube May 21, 2024

Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...

Company Deals

Blue Sail Medical Subsidiary Secures RMB 100 Million Investment to Expand Operations

Fineline Cube May 21, 2024

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that Blue Sail Biosensors Medical...

Company Deals

Jiayue Pharmaceutical’s JYP0015 Secures $365 Million Licensing Agreement with Erasca

Fineline Cube May 21, 2024

Guangzhou Jiayue Pharmaceutical Technology Co., Ltd, a Chinese pharmaceutical company, has entered into a licensing...

Policy / Regulatory

China’s CDE Reports Record High in Clinical Trials for Innovative Drugs in 2023

Fineline Cube May 21, 2024

The Center for Drug Evaluation (CDE) has released its annual report, highlighting the growth in...

Company Drug

Gilead’s Seladelpar Shows Interim Benefits in PBC-Related Itch Clinical Trial

Fineline Cube May 21, 2024

Gilead Sciences (NASDAQ: GILD) has announced interim results from a long-term study assessing the safety...

Company

AstraZeneca Commits $1.5 Billion to Build Singapore-Based ADC Manufacturing Facility

Fineline Cube May 21, 2024

UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) has announced plans for a $1.5 billion greenfield...

Policy / Regulatory

NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels

Fineline Cube May 21, 2024

The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the...

Company Medical Device

BGI Genomics Delays Market Filing for BRCA1/2 Detection Kit Due to Incomplete Data

Fineline Cube May 21, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Medical Device

Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads

Fineline Cube May 21, 2024

Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with...

Company Drug

BMS’s Sotyktu Sustains Clinical Response in Long-Term Psoriasis Treatment

Fineline Cube May 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for...

Policy / Regulatory

China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation

Fineline Cube May 21, 2024

The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...

Company Deals

Pharmaron and AstraZeneca Enter Sweeping Partnership to Span Drug Development Services

Fineline Cube May 21, 2024

Pharmaron Beijing Co., Ltd, a leading Contract Research Organization (CRO) based in Beijing (HKG: 3759;...

Company Drug

Jiangsu Hengrui’s SHR1905 Anti-TSLP mAb Gets Green Light for COPD Clinical Trial

Fineline Cube May 21, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, announced that it...

Company Drug

Innovent Biologics’ IBI311 New Drug Application Accepted for Review by China’s CDE

Fineline Cube May 21, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Deals Digital Hospital

Union Hospital Teams Up with Baidu Health for AI-Enhanced Outpatient Services

Fineline Cube May 20, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, has entered into a...

Company Drug

Zai Lab and Innoviva Win China Approval for SUL-DUR to Treat Hospital-Acquired Pneumonia

Fineline Cube May 20, 2024

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, in collaboration with US...

Posts pagination

1 … 352 353 354 … 660

Recent updates

  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
  • Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion
  • Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Company Drug

Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer

Company

Amgen Announces $300M Additional Investment in US Manufacturing Network, Bringing Total Recent Commitments to Over $3 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.